Elsevier

Advanced Drug Delivery Reviews

Volume 60, Issue 12, 15 September 2008, Pages 1329-1346
Advanced Drug Delivery Reviews

Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer

https://doi.org/10.1016/j.addr.2008.04.013Get rights and content

Abstract

The recent developments of nuclear medicine in oncology have involved numerous investigations of novel specific tumor-targeting radiopharmaceuticals as a major area of interest for both cancer imaging and therapy. The current progress in pharmaceutical nanotechnology field has been exploited in the design of tumor-targeting nanoscale and microscale carriers being able to deliver radionuclides in a selective manner to improve the outcome of cancer diagnosis and treatment. These carriers include chiefly, among others, liposomes, microparticles, nanoparticles, micelles, dendrimers and hydrogels. Furthermore, combining the more recent nuclear imaging multimodalities which provide high sensitivity and anatomical resolution such as PET/CT (positron emission tomography/computed tomography) and SPECT/CT (combined single photon emission computed tomography/computed tomography system) with the use of these specific tumor-targeting carriers constitutes a promising rally which will, hopefully in the near future, allow for earlier tumor detection, better treatment planning and more powerful therapy. In this review, we highlight the use, limitations, advantages and possible improvements of different nano- and microcarriers as potential vehicles for radionuclides delivery in cancer nuclear imaging and radiotherapy.

Introduction

Cancer has been one of the major social and health concerns for the last ten decades, albeit the milestones achieved in both diagnosis and treatment procedures. The use of nuclear medicine applications in oncology is of a particular importance as a rapidly developing therapeutic and diagnostic multimodality.

The investigation of novel tumor-targeting radiopharmaceuticals is currently one of the potential fields of interest for researchers for both tumor scintigraphy and/or treatment. Radiopharmaceuticals are dosage forms consisting of two components, a carrier and a trace amount of a radionuclide with a defined radiation type(s). Therefore, the efficacy of a radiopharmaceutical is determined by these two components. In tumor radiotherapy, the therapeutic effect is due to the tumoral absorption of alpha (α) or beta (β) radiation energy emitted by the radionuclide. The ideal radiopharmaceutical should convey the radioactive nuclide quantitatively to the tumor tissue, with no radiation reaching the normal tissues. In this context, the recent progress in pharmaceutical nanotechnology field has been efficiently exploited in developing promising approaches based on the design of novel nano- and microcarriers, which function to improve the outcome of radiotherapy and the quality of diagnosis [1].

It is well established that nanomedicine is currently attracting a worldwide interest of researchers who aim to dedicate this technology to develop novel approaches in cancer imaging, molecular diagnosis and targeted therapy [2]. Anticancer drug delivery systems are of the most investigated research areas in nanomedicine. Numerous investigations have shown that incorporating anticancer agents in nanoparticulate or microparticulate carriers would provide a useful means for controlling the tissular and cellular distribution profiles of these agents. The rationale behind these approaches is to combine a drug controlled-release fashion with a targeted delivery in order to provide more efficient and less harmful solutions, thus, surmounting the limitations often encountered in conventional chemotherapy [3], [4].

Among these different systems, particulate nanoscale carriers (i.e. liposomes, nanoparticles) have gained most of the researchers' attention due to their potential qualities. They are classified into three generations. The first generation of nanocarriers is known for its rapid clearance from the blood stream and high uptake by the macrophages of the reticuloendothelial system (RES) (e.g. Kupffer cells of the liver) due to the opsinisation processes occurring at the surface of these carriers following an intravenous administration. Therefore, many research papers demonstrated practically the possibility to beneficiate from such biodistribution profile as a passive targeting method for the treatment of hepatic cancers [5], [6].

To reduce their toxicity, overcome the RES capture and prolong their blood circulation time, the nanocarriers surface properties have been modified by covalently binding hydrophilic poly(ethylene glycol) (PEG) chains leading to the emergence of the second generation; PEGylated nanocarriers [7], [8]. This generation is exemplified in the work of Brigger et al. who reported an enhancement of the brain tumor uptake of PEGylated nanoparticles compared with conventional nanocarriers [9], [10]. A further development on the nanocarriers was carried out by binding specific recognition ligands (e.g. antibodies, folic acid) to their surface [11], [12]. This allows an active rather than passive targeting of the cancerous cells framing the third generation of nanocarriers.

Targeted vectors typically have an architecture comprised of a building polymeric or lipidic matrix, a targeting moiety being any molecule that selectively recognizes and binds to ligands on target cells, and a loaded diagnostic or therapeutic agent. Based on this general assembly, several types of carriers have been elaborated in the last few decades. These carriers include, among others, submicronic systems like liposomes, nanoparticles, micelles and dendrimers, micoparticulate systems (microparticles) and lastly hydrogels (Fig. 1). These different vectors have shown to be auspicious means in the delivery of anticancer drugs [13], [14], [15], [16], [17], [18]. Therefore, depending on their interesting characteristics which confer an improved intra-tumoral delivery for the therapeutic molecules, all of these vectors were investigated for the delivery of radionuclides for both cancer nuclear imaging and radiotherapy.

In nuclear imaging, radiolabelled carriers can be applied as non-invasive diagnostic Emfietzoglouagents to provide both functional and structural data about the malignant tissues and their surroundings. The different nuclear medicine imaging modalities include single photon emission-computed tomography (SPE/CT), positron emission tomography (PET) and positron emission tomography-computed tomography (PET/CT). These imaging techniques are all of great clinical value for earlier recognition of the presence and the extent of malignancy based on the fact that biochemical changes generally precede anatomical changes [19]. Cancer radiotherapy, in turn, involves external and internal radiotherapy routes. In this framework, the radiolabelled nano- and microcarriers are designed for internal radiotherapy via intra-tumoral or systemic administration routes in the aim of obtaining a localised radiation in the interior of the tumor area avoiding radiation dissemination within the body [1]. In this paper, we review the utilisations, limitations and advantages of the different radiopharmaceutical nano- and microcarriers, including liposomes, microparticles, nanoparticles, micelles, dendrimers and hydrogels, for tumor imaging and radiotherapy.

Section snippets

Radionuclides for nuclear imaging

Radionuclide imaging is commonly devised into two general modalities; single photon emission computed tomography (SPECT) and positron emission tomography (PET). Generally, typical imaging studies include dynamic or static imaging and in vivo function tests. Dynamic imaging provides clinicians with necessary data about biological turnover of radioisotopes in different body compartments and organs. Single-photon radionuclides emit gamma (γ) rays in the energy range of approximately 75 to 360 keV

Liposomes

Liposomes are self-assembling vesicles with an inner aqueous compartment surrounded by a phospholipidic bilayer [39]. Liposomes can encompass hydrophilic agents in the inner aqueous compartment or/and lipophilic agents in the outer lipid membrane. Accordingly, different modalities to encapsulate radionuclides in liposomes or to radiolabel them can be applied in consistence with the solubility of the utilised radionuclide or radionuclide conjugate [40], [41].

Conclusion

Great steps are being taken every day in pharmaceutical nanotechnology towards changing the scale and methods of radioisotope delivery for a better future of cancer radiotherapy and imaging. Different radiolabelled nano- and microcarriers have been elaborated for passive or active targeting of tumors with promising results in spite of the fact that not all these targeting mechanisms are actually clearly understood. Many of these carriers have been successfully applied in both preclinical and

Acknowledgement

The author aknowledge the companies: Advanced Aceelerator Applications and Cerma for the financial help and the scientific collaboration through the research grant Eureka and the project INBARCA.

References (231)

  • S. Banerjee et al.

    Evolution of Tc-99m in diagnostic radiopharmaceuticals

    Semin. Nucl. Med.

    (2001)
  • A.M. Peters et al.

    The value of indium-labelled leucocytes in clinical practice

    Blood Rev.

    (1987)
  • A.V. Christoforidou et al.

    Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes

    Biol. Blood Marrow Transplant.

    (2007)
  • B. Gray et al.

    Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer

    Ann. Oncol.

    (2001)
  • Z. Zhang et al.

    Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25

    Blood

    (2006)
  • M. Jaggi et al.

    Liposomes as carriers of technetium-99m glucoheptonate for liver imaging

    Int. J. Pharm.

    (1991)
  • I. Ogihara-Umeda et al.

    Development of a liposome-encapsulated radionuclide with preferential tumor accumulation—the choice of radionuclide and chelating ligand

    Int. J. Rad. Appl. Instrum. B.

    (1992)
  • W.T. Phillips

    Delivery of gamma-imaging agents by liposomes

    Adv. Drug Deliv. Rev.

    (1999)
  • M. Udayachander et al.

    Tumor targeting potential of liposomes encapsulating Ga-67 and antibody to Dalton's lymphoma associated antigen (anti-DLAA)

    Int. J. Radiat. Oncol. Biol. Phys.

    (1987)
  • A. Bao et al.

    Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection

    Int. J. Pharm.

    (2006)
  • H.E. Wang et al.

    Internal radiotherapy and dosimetric study for 111In/177Lu-pegylated liposomes conjugates in tumor-bearing mice

    Nucl. Instrum. Meth. A

    (2006)
  • L. Geng et al.

    Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay

    J. Control. Release

    (2004)
  • S. Dagar et al.

    VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery

    J. Control. Release

    (2001)
  • S. Dagar et al.

    VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies

    J. Control. Release

    (2003)
  • N. Oku et al.

    Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography

    Biochim. Biophys. Acta

    (1996)
  • N. Oku

    Delivery of contrast agents for positron emission tomography imaging by liposomes

    Adv. Drug Deliv. Rev.

    (1999)
  • N. Oku et al.

    Glucuronate-modified, long-circulating liposomes for the delivery of anticancer agents

    Methods Enzymol.

    (2005)
  • R. Kunstfeld et al.

    Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a “humanized” SCID mouse model

    J. Invest. Dermatol.

    (2003)
  • U. Häfeli et al.

    A lipophilic complex with 186Re/188Re incorporated in liposomes suitable for radiotherapy

    Int. J. Rad. Appl. Instrum. B.

    (1991)
  • G. Henriksen et al.

    Sterically stabilized liposomes as a carrier for α-emitting radium and actinium radionuclides

    Nucl. Med. Bio.

    (2004)
  • H. Yanagie et al.

    Application of boron-entrapped stealth liposomes to inhibition of growth of tumour cells in the in vivo boron neutron-capture therapy model

    Biomed. Pharmacother.

    (2006)
  • C.Y. Ke et al.

    Folate-receptor-targeted radionuclide imaging agents

    Adv. Drug Deliv. Rev.

    (2004)
  • U.O. Hafeli et al.

    Fibrin glue system for adjuvant brachytherapy of brain tumors with 188Re and 186Re-labeled microspheres

    Eur. J. Pharm. Biopharm.

    (2007)
  • M.D. Wang et al.

    Nanotechnology for targeted cancer therapy

    Exp. Rev. Anticancer Ther.

    (2007)
  • N. Chiannilkulchai et al.

    Hepatic tissue distribution of doxorubicin-loaded nanoparticles after, I.V. administration in reticulosarcoma M 5076 mestastases-bearing mice

    Cancer Chemother. Pharmacol.

    (1990)
  • X.H. Jiang et al.

    The antihepatoma effect of lyophilized aclacinomycin A polyisobutylcyanoacrylate nanoparticles in vitro and in vivo

    Yao Xue Xue Bao

    (1995)
  • R. Gref et al.

    Biodegradable long-circulating polymeric microspheres

    Science

    (1994)
  • I. Brigger et al.

    Poly(etylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting

    J. Pharmacol. Exp. Ther.

    (2002)
  • P. Kocbek, N. Obermajer, M. Cegnar, J. Kos, J. Kristl. Targeting cancer cells using PLGA nanoparticles surface modified...
  • A.S. Zidan et al.

    Formulation of anastrozole microparticles as biodegradable anticancer drug carriers

    AAPS Pharm. Sci. Technol.

    (2006)
  • S. Li et al.

    Self-assembled poly(butadiene)-b-fpoly(ethylene oxide) polymersomes as paclitaxel carriers

    Biotechnol. Prog.

    (2007)
  • A. Rueda Dominguez et al.

    Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis

    Clin. Transl. Oncol.

    (2005)
  • R.E. Coleman

    Radionuclide Imaging in Cancer Medicine. Cancer Imaging. Cancer in Medicine

    (2003)
  • M. Dietlein et al.

    Imaging of central nervous system lymphomas with iodine-123 labeled rituximab

    Eur. J. Haematol.

    (2005)
  • O. Konuk et al.

    Orbital gallium-67 scintigraphy in Graves' ophthalmopathy

    Thyroid

    (2002)
  • A.M. Kirby et al.

    The role of FDG PET in the management of lymphoma: practical guidelines

    Nucl. Med. Commun.

    (2007)
  • G. Lliakis

    The role of DNA double strand breaks in ionizing radiation-induced killing of eukaryotic cells

    BioEssays

    (1991)
  • J. Julow et al.

    Stereotactic intracavitary irradiation of cystic craniopharyngiomas with yttrium-90 isotope

    Prog. Neurol. Surg.

    (2007)
  • S. Sergieva et al.

    Nuclear medicine approaches in the monitoring of thyroid cancer patients

    J. BUON.

    (2006)
  • M.P. Yaneva et al.

    Radionuclide therapy of cancer patients with bone metastases

    Folia Med.

    (2005)
  • Cited by (0)

    This review is part of the Advanced Drug Delivery Reviews theme issue on “Delivery Systems for the Targeted Radiotherapy of Cancer”.

    View full text